PIII vs. VMD, BDSX, SERA, QIPT, EUDA, XGN, TOI, BNR, ENZ, and CCM
Should you be buying P3 Health Partners stock or one of its competitors? The main competitors of P3 Health Partners include Viemed Healthcare (VMD), Biodesix (BDSX), Sera Prognostics (SERA), Quipt Home Medical (QIPT), EUDA Health (EUDA), Exagen (XGN), Oncology Institute (TOI), Burning Rock Biotech (BNR), Enzo Biochem (ENZ), and Concord Medical Services (CCM). These companies are all part of the "healthcare" industry.
P3 Health Partners vs.
Viemed Healthcare (NASDAQ:VMD) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.
P3 Health Partners received 1 more outperform votes than Viemed Healthcare when rated by MarketBeat users. However, 42.86% of users gave Viemed Healthcare an outperform vote while only 26.67% of users gave P3 Health Partners an outperform vote.
74.2% of Viemed Healthcare shares are held by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are held by institutional investors. 20.0% of Viemed Healthcare shares are held by insiders. Comparatively, 17.9% of P3 Health Partners shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
P3 Health Partners has a consensus target price of $2.38, indicating a potential upside of 1,041.83%. Given P3 Health Partners' higher probable upside, analysts plainly believe P3 Health Partners is more favorable than Viemed Healthcare.
Viemed Healthcare has a net margin of 4.87% compared to P3 Health Partners' net margin of -6.95%. Viemed Healthcare's return on equity of 8.72% beat P3 Health Partners' return on equity.
In the previous week, Viemed Healthcare had 1 more articles in the media than P3 Health Partners. MarketBeat recorded 3 mentions for Viemed Healthcare and 2 mentions for P3 Health Partners. Viemed Healthcare's average media sentiment score of 1.24 beat P3 Health Partners' score of 0.49 indicating that Viemed Healthcare is being referred to more favorably in the media.
Viemed Healthcare has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, P3 Health Partners has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.
Viemed Healthcare has higher earnings, but lower revenue than P3 Health Partners. P3 Health Partners is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.
Summary
Viemed Healthcare beats P3 Health Partners on 15 of the 19 factors compared between the two stocks.
Get P3 Health Partners News Delivered to You Automatically
Sign up to receive the latest news and ratings for PIII and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
P3 Health Partners Competitors List
Related Companies and Tools
This page (NASDAQ:PIII) was last updated on 2/21/2025 by MarketBeat.com Staff
